Stepan Company (NYSE: SCL) — A No-Moat Commodity Cyclical Dressed in a Specialty Label, Waiting for the Knife to Land

Sector: Materials — Specialty Chemicals (GICS sub-industry: Specialty Chemicals) Published: June 7, 2026 Price at writing: $51.28 (2026-06-05 close) · Market cap: ~$1.165B · Enterprise value: ~$1.68–1.74B · 52-week range: $41.82–$68.00 Primary filings: FY2025 10-K (filed 2026-02-26); Q1 2026 10-Q (filed 2026-05-06). SEC CIK 0000094049. Standing note: The body of this article (Executive Summary through the Source Appendix, sections 1–15) carries no investment recommendation and no price target. It discusses valuation only as embedded expectations and explicit-assumption scenarios. The single, deliberate exception is the Claude’s Take block immediately below, which is fenced off as a subjective view.

⚡ Claude’s Take

This block is the author’s own subjective, independent opinion. It is general information, not investment advice. Everything from the Executive Summary onward (sections 1–15) is deliberately recommendation-free and price-target-free; that view is confined entirely to this fenced block.

Verdict: HOLD / accumulate-on-weakness — a no-moat deep-cyclical worth owning cheaper, not here. Constructive entry zone ~$40–46 (≈0.85–0.95× tangible book of ~$49/sh, ~6× normalized FCF); fair-value band ~$48–66 on a commodity multiple; bull optionality to ~$85+ only if the specialty re-rate is earned. Not a short.

Tag: “Wait for the knife to land.”

Stepan is a textbook capital-cycle setup wearing a misleading “specialty” label: a ~$2.3B-revenue, mostly-commodity surfactant processor (71% of sales at a ~4% operating margin) trading below book (P/B 0.94×) at the cheapest ~7th percentile of its own decade, at a genuine cyclical-and-self-help trough. The bull narrative is real and well-evidenced — Project Catalyst (~$100M pretax savings, supply rationalization in an oversupplied industry), the Pasadena alkoxylation plant ramping into specialty/low-1,4-dioxane chemistry, a 58-year dividend-increase streak, and trough GAAP earnings that genuinely understate mid-cycle power (~$280–310M normalized EBITDA, ~$4.50–5.50 EPS vs. $2.05 reported). That is the case for owning it. The reason I won’t pay $51 is discipline, not disbelief: the business does not earn its cost of capital (FY25 after-tax ROIC ~3.6% vs. ~8–9% WACC; even normalized ROIC only reaches ~6–7%), and an earnings-power value on steady-state earnings (~$810M equity, ~$36/sh) sits below the current market cap — so at $51 you are already paying for a recovery that is unproven in a business with no moat to protect the savings once they arrive. In a no-moat commodity, cost-outs get competed away as price.

This is a contrarian/value-with-a-catalyst framing, not a quality-compounder and not momentum. The asymmetry is favorable at the right price: the base case (~$61–73) sits above the current quote, but the bear case (~$25–38) pierces tangible book (Q1’26 impairments prove the carrying value isn’t fully recoverable), and the dividend is not currently covered by organic FCF (FY25 FCF $25.4M < $35.0M paid) — a cut would confirm the bear and de-rate the stock. So I want a margin of safety the $51 price doesn’t give: buy nearer tangible book (~low-$40s), where the bear is partly pre-paid and the recovery option is closer to free. Conviction: low-to-medium. Flips bullish on hard evidence the Catalyst savings are sticking in the P&L — sequential gross-margin expansion through Q2–Q3 2026 and Pasadena specialty volumes lifting Surfactant mix, pointing normalized EBITDA visibly above ~$270M. Flips bearish on a dividend cut or a third consecutive quarter of structural (not weather/timing) surfactant volume erosion, which would say the cost-outs are being given back and the trough is a plateau.

1. Executive Summary

Stepan Company is a ~$2.3 billion-revenue, business-to-business manufacturer of intermediate and specialty chemicals — Surfactants (71% of FY2025 sales), Polymers (25%), and Specialty Products (3.5%) — sold to other manufacturers who formulate them into detergents, personal-care products, rigid-foam insulation, crop and oilfield chemicals, and food/pharma ingredients. The defining financial fact is the segment margin pyramid: the dominant Surfactants segment earns a commodity-like ~4% operating margin, while the only genuinely attractive franchise — Specialty Products/MCT at ~31% operating margin — is too small (3.5% of sales) to move the consolidated needle. Reported revenue is largely raw-material pass-through; true organic volume growth is low-single-digit and lumpy.

This is a no-moat-to-narrow-moat business at a cyclical-and-self-help trough. The decisive evidence is returns: FY2025 after-tax ROIC of ~3.6% and ROE of ~3.9% against an estimated ~8–9% WACC — the business is currently destroying economic value, and even at the 2021–22 super-cycle peak returns only reached the cost of capital (ROIC ~8–9%, ROE ~12%). Margins compressed ~530 bp from the 2021 peak. Q1 2026 produced a GAAP net loss of $41.4M (−$1.81/sh), but that is ~96% a non-cash $65.4M restructuring/impairment charge (Project Catalyst); adjusted net income was $10.3M ($0.45). Quality of earnings is otherwise clean — conservative adjusted metrics (adjusted EBITDA $198.9M is below reported because it strips out a $15.9M asset-sale gain), CFO running above net income, an overfunded pension, and a long, stable Deloitte/ICFR record.

The investment debate is cyclical trough vs. structural decline. The bull case rests on three self-help levers: (1) Project Catalyst — ~$100M of pretax savings over two years via footprint rationalization (closing Fieldsboro NJ; decommissioning assets at Millsdale IL and Stalybridge UK); (2) the Pasadena, TX alkoxylation plant (~$265M, ~20% over budget and ~18 months late) ramping from ~80% utilization in 2026 to full in 2027, enabling specialty alkoxylates and 1,4-dioxane-free surfactants — a genuine regulatory tailwind; and (3) deleveraging (net debt ~$511M, ~2.6×) plus asset monetization (a $30M Millsdale land sale closing 2H’26). If these land, normalized earnings power is roughly double the trough (~$280–310M adjusted EBITDA, ~$4.50–5.50 EPS). The bear case is that in a no-moat commodity core, the savings get competed away in price, surfactant volume is structurally (not cyclically) eroding, and the uncovered dividend (FY25 organic FCF $25.4M < $35.0M paid) eventually forces a cut.

Valuation reflects exactly this stand-off. At $51, the market pays ~8× trough EBITDA = ~6× normalized EBITDA — it underwrites a partial recovery while withholding credit for the full Catalyst program, a specialty re-rating, and a cycle turn. The stock is statistically cheap versus its own decade (P/B 0.94×, ~7th percentile) and on normalized earnings, but not cheap on steady-state earnings-power value (which sits below the market cap) — the price already embeds recovery optionality. The scenario fan is wide and two-sided: bear ~$25–38, base ~$61–73, bull ~$87–112, with the current price at the low end of base. The master swing variable is whether Project Catalyst savings and Pasadena specialty volumes reach the P&L and earn a re-rating, or are competed away at an unchanged commodity multiple. Management (CEO Luis Rojo, ex-CFO, since Oct-2024; CFO Ruben Velasquez, ex-3M, since Jul-2025) has a sensible, ROIC-gated incentive structure and is taking the right self-help actions; insiders, however, are passive (one token open-market buy in three years) — no conviction signal at a below-book trough.

2. Business Overview

What Stepan is. Stepan Company is a ~$2.3B-revenue manufacturer of intermediate and specialty chemicals sold business-to-business to other manufacturers, who blend or formulate them into end products (FY2025 10-K, Item 1). It is not a consumer brand owner; it sells the active and functional ingredients that go into detergents, shampoos, insulation foam, crop chemicals and food/pharma products. The company reports three segments: Surfactants, Polymers and Specialty Products.

How it makes money. Stepan converts purchased raw materials (petroleum- and plant/oleochemical-derived feedstocks plus ethylene oxide it consumes captively) into chemical intermediates. Selling prices move largely with raw-material costs — the FY2025 and FY2024 segment bridges show price changes “primarily due to the pass-through of higher [lower] raw material costs” (FY2025/FY2024 10-K MD&A). The economic question is therefore not headline revenue but the spread (gross profit per pound) Stepan captures over feedstock, and how much of that spread is durable. The answer, segment by segment, is mostly “thin.”

Segment net sales and operating income (FY2025 10-K segment note)

Segment margin structure (derived from segment note)

This table is the most important fact about Stepan. The segment that is 71% of sales (Surfactants) earns a ~4% operating margin; the only segment with attractive economics — Specialty Products at ~31% operating margin — is 3.5% of sales and ~19% of segment operating income. Consolidated GAAP gross margin is ~11.5% (FY2025).

Surfactants — surfactants are surface-active agents providing detergency, wetting/foaming, emulsification, dispersion and biocidal action (Item 1). End markets: consumer laundry & cleaning, personal care (shampoo/body wash), disinfectant quats, agricultural emulsifiers (crop), oilfield, and industrial/institutional cleaning. The bulk is commodity-grade chemistry sold into price-competitive consumer end markets; the differentiated slices are crop, oilfield, industrial cleaning, and newer low-1,4-dioxane / sulfate-free chemistries. Geography skews North America (~57%) and Latin America (~21%).

Polymers — polyurethane polyols (rigid foam for construction thermal insulation; the largest piece), polyester resins / CASE (coatings, adhesives, sealants, elastomers), and phthalic anhydride (PA), a true commodity intermediate. Polymers is ~54% North America and ~38% Europe; European construction demand has been weak. PA is the most commodity-like product Stepan makes — FY2025 NA polymer volumes jumped because a competitor exited the PA market (FY2025 10-K MD&A), the textbook signature of a commodity.

Specialty Products — food, flavor and pharmaceutical ingredients, led by the medium-chain triglyceride (MCT) product line. Small but the highest-margin, most-differentiated business; sales are spec-locked and customer-qualified (regulated food/pharma). FY2025 operating margin 31%.

Revenue quality. Demand is recurring/consumable (chemicals consumed in customers’ production), so there is no install-base or long-term contract recurring-revenue moat — it is repeat transactional volume. But it is genuinely cyclical and FX-exposed: tied to consumer staples demand (defensive), construction/insulation (cyclical, currently weak in Europe), agriculture (seasonal), and oilfield (cyclical). No single customer exceeded 10% of consolidated sales in 2023, 2024 or 2025 (credit-risk note) — diversification is real, and a double-edged sword: it limits concentration risk but also confirms Stepan lacks anchor customers locked into its platform.

Verdict: A diversified, mostly-commodity intermediate-chemicals maker whose dominant segment earns commodity-like ~4% operating margins. The business model is largely raw-material pass-through with a thin, contestable processing spread; genuine value-add economics exist only in Specialty Products (3.5% of sales) and in narrow specialty surfactant/polyol niches. Revenue is recurring in the consumable sense but cyclical and FX-exposed. Structurally a low-margin processor, not a specialty-chemicals compounder — despite the “specialty” label.

3. Competitive Position

The moat test

The decisive evidence is the return on capital. A durable competitive advantage must show up as ROIC sustained above the cost of capital; otherwise the “moat” is a story that no financial outcome depends on.

• FY2025 ROE = 3.9% (net income $46.9M / average equity ~$1,207M).
• FY2025 pretax operating ROIC ≈ 4.6%; after-tax ROIC ≈ 3.6% (operating income $78.5M, NOPAT ~$61.5M at a 21.7% tax rate, over ~$1.7B invested capital including ~$0.45B debt).

Against an estimated ~8–9% cost of capital, Stepan is currently earning well below its cost of capital — it is destroying economic value at the consolidated level (the return figures are fact). Even allowing that 2024–2025 are cyclically depressed (weak European construction, soft Asia, Mexican price competition, raw-material whipsaw), single-digit ROIC through a full cycle is the financial signature of a business without a broad moat. A moated specialty-chemicals franchise (Croda, for instance, historically earns 20%+ ROIC) looks nothing like this.

Naming the (absent) advantage

The three genuine advantage types are supply/cost, demand/customer captivity, and economies-of-scale + captivity. Testing Stepan:

• Customer captivity / switching costs — largely absent. Surfactant and PA buyers can and do dual-source spec-able intermediates; no customer is >10% of sales; pricing is set by raw-material pass-through, not by lock-in. Management’s own FY2024 disclosure attributes lower surfactant prices to “increased competitive pressure” — the opposite of pricing power. Real switching costs exist only where products are qualified into a regulated formulation: the food/pharma MCT line and certain specialty surfactants/polyols. That is genuine demand captivity — but it is confined to well under 10% of the company, and the consolidated 3.6% ROIC proves it is not broad enough to matter.
• Economies of scale + captivity — fails the captivity leg. Stepan is the largest merchant (non-captive) surfactant producer in North America, which confers real scale in production, logistics and R&D/technical service. But scale only becomes a moat when paired with customer captivity within a bounded market. Stepan has the scale and not the captivity, so the scale does not convert into excess returns — it competes against far larger diversified majors (below) on globally-traded molecules.
• Supply / cost advantage — partial and regional only. The most defensible claim is a regional cost/logistics edge: local US ethoxylation (ethylene oxide) capacity gives freight advantage and import-substitution leverage in North American surfactants/oilfield, and captive EO avoids merchant-market exposure. This is real but modest, geographically bounded, and not earning above-cost-of-capital returns.

Competitive set

Most surfactant competitors are multiples of Stepan’s size with deeper integration. Stepan competes, per its own 10-K, on “product performance, price, technical assistance, the ability to meet the specific needs of individual customers and availability of sufficient capacity” — management argues this lets it “compete on bases other than price alone” (Item 1). The financials say price still dominates: spreads compress when competitors push (FY2024) and when demand softens (FY2025 commodity laundry/cleaning).

The capital-cycle signal

The single most revealing recent datapoint: in Q1 2026, Stepan booked a $65.4M pre-tax restructuring charge — entirely in Surfactants — including $62.4M of asset impairments at Fieldsboro NJ ($43.0M), Millsdale IL ($14.3M) and Stalybridge UK ($5.1M) (Q1 2026 10-Q). Stepan is writing down and closing commodity surfactant capacity even as it ramps the new Pasadena, TX alkoxylation plant (started up April 2025). In capital-cycle terms this is supply rationalization in an over-supplied commodity — a footprint a moated franchise does not have. The simultaneous Pasadena build is a repositioning bet (specialty alkoxylates, 1,4-dioxane-free chemistry), not capacity-driven moat extension. Combined with the PA competitor exit boosting FY2025 polymer volumes, the picture is one of unstable share in commodity lines — failing the market-share-stability test.

Is the Tier-2/3 strategy a moat?

Management’s “scale to win” pitch in Tier-2/Tier-3 customers (smaller brands and private label) is a distribution/service niche, not customer captivity. Serving fragmented smaller accounts with a broad portfolio plus formulation/technical service may earn better per-account margins than selling commodity volumes to Tier-1 majors, and is a sensible defensive move away from Tier-1 price wars — but it is chasing fragmented low-margin demand, and Stepan does not separately quantify its revenue or returns. On current evidence it is a strategy, not a moat.

Verdict: No durable, company-wide moat. The dominant Surfactants segment is a thin-spread commodity processor competing against far larger majors, with no customer captivity and pricing set by raw-material pass-through; consolidated ROIC (~3.6% after-tax) and ROE (3.9%) sit well below cost of capital, and Q1 2026 impairments confirm over-supplied commodity economics. The only genuine competitive advantages — formulation/qualification switching costs in Specialty Products/MCT, and a modest regional cost/logistics edge in NA surfactants — are real but too narrow to lift the whole. Classification: at best a bounded regional supply/cost advantage plus a small pocket of demand captivity; in aggregate, a no-moat-to-narrow-moat commodity business wearing a “specialty” label.

4. Growth History & Forward Opportunities

Strip out the pass-through

Reported “sales growth” at Stepan is mostly raw-material price pass-through, not real growth. The volume/price/FX bridges make this explicit (10-K MD&A):

So in FY2025 the headline +7% revenue was +1% real volume (+2% organic ex-Philippines divestiture); the rest was passing higher feedstock costs along. In the 71%-of-sales Surfactants segment, volume actually fell 2% on weak commodity laundry/cleaning demand — the “+9% sales” was entirely pass-through.

Multi-year, the pattern is low, lumpy organic volume:

• FY2024: consolidated sales −6% (mostly raw-material deflation) but volume +1% (Surfactants +2%, Specialty +7%, Polymers −4%) (FY2024 10-K).
• FY2025: sales +7% / volume +1–2% organic.
• Q1 2026: organic net sales +4% but organic volume flat; Surfactant volume −2%, Polymer volume −6%, Specialty Products +24% sales on +30% MCT volume (Q1 2026 10-Q).

Where the real (small) growth is

• Specialty Products / MCT — the genuine high-quality engine. +15% volume in FY2025, +30% in Q1 2026, at 31% operating margin. This is differentiated, qualified, growing volume and high-margin — exactly what the rest of Stepan is not. But it is only 3.5% of sales; even strong growth here moves the consolidated needle slowly.
• Polymer volume “recovery” is partly one-off. FY2025 NA polymer volume +20% was driven by phthalic-anhydride volume more than doubling on a competitor’s market exit and non-recurrence of 2024 Millsdale operational problems. That is share captured from a commodity exit and an operational rebound — not durable organic demand growth — and Q1 2026 polymer volume already fell 6%.
• Pasadena alkoxylation (specialty optionality). Commissioned April 2025; ramping toward higher utilization through 2026–2027. The strategic logic — specialty alkoxylates, 1,4-dioxane-free and sulfate-free surfactant chemistries, mix-up away from commodity consumer surfactants — is sound, and is the main bull-case growth lever. But it is unproven: there is no filing evidence yet of structural consolidated margin uplift, and it is being commissioned while legacy surfactant sites are impaired and closed (net repositioning, not net new capacity).
• Crop / oilfield / industrial cleaning / Tier-2-3. Management says these grow double-digit in volume. Plausible and strategically rational (away from Tier-1 commodity), but Stepan does not disclose their revenue or returns separately, so the claims cannot be validated from filings and must be treated as a hypothesis.

Quality assessment

Strip the pass-through and what remains is low-single-digit, lumpy organic volume growth in a mostly-commodity portfolio, with one small genuinely-attractive franchise (Specialty/MCT) and one unproven repositioning bet (Pasadena specialty alkoxylates). The growth that exists in the commodity lines is partly competitor-exit-driven (PA) rather than self-generated. There is no evidence of compounding, scale-driven margin expansion: consolidated operating income has been range-bound ($58.6M → $70.5M → $78.5M FY2023–25) and ROIC remains below cost of capital across the period.

Verdict: Low-to-mixed-quality growth. Headline revenue growth is largely an accounting artifact of raw-material pass-through; true organic volume growth is low single-digit and lumpy. The only high-quality growth (volume + margin + differentiation) is in Specialty Products/MCT, which is too small to re-rate the company, plus the unproven Pasadena specialty-alkoxylate optionality. The diversification-away-from-commodity strategy is the right idea, but on current filing evidence it is offsetting commodity erosion rather than driving durable, profitable, above-cost-of-capital growth.

5. Industry Dynamics

Stepan is an intermediate (“merchant”) chemicals producer occupying the middle of three distinct value chains — surfactants, polymers (polyurethane polyols / phthalic anhydride), and specialty products. To judge whether Stepan sits in good or bad industries, each must be assessed on its own structure, profit pool, and position in the capital cycle. The short answer, developed below, is mixed and segment-dependent: the consumer-cleaning core is a structurally mediocre commodity business, partly redeemed by higher-value niches and a genuine regulatory share-shift tailwind; polymers are cyclically depressed but structurally average; phthalic anhydride is structurally poor. The redeeming feature today is where we are in the capital cycle — the broad chemical industry is rationalizing capacity hard, which is the supply-side condition that precedes a returns recovery.

5.1 Value-chain position — squeezed in the middle

Stepan does not sell to consumers. It sells intermediates to manufacturers — chiefly large consumer-packaged-goods (CPG) formulators (P&G, Unilever, Henkel, Clorox-type accounts) plus Tier-2/3 and industrial customers — and it buys its principal feedstocks from a concentrated set of upstream suppliers: Southeast-Asian palm and coconut growers for natural oleochemicals, and petrochemical producers for ethylene oxide and other petro-derived inputs (FY2025 10-K). This mid-stream position is structurally the weakest link in a value chain: it is pressured from both ends — concentrated feedstock supply on one side (>75% of world coconut/palm-kernel oil originates in Indonesia, Malaysia and the Philippines) and large, sophisticated, concentrated CPG buyers on the other. The 10-K is candid that Stepan “does not sell directly to the retail market,” competes on “product performance, price, technical assistance, the ability to meet the specific needs of individual customers and availability of sufficient capacity,” and that these allow it to “compete on bases other than price alone” — an admission that in the commodity portion of its book (laundry, dish), price is the dominant axis.

5.2 Segment 1 — Surfactants (70%+ of sales): large, fragmented, low-growth, pass-through

The single most important structural fact about this segment is that reported sales are a poor proxy for demand. Surfactant contracts are largely raw-material pass-through; FY2025’s +9% segment sales rose on higher average selling prices (feedstock pass-through), while volume fell ~1–2% ex-divestiture (SCL FY2025 10-K). Sales swing with oleochemical/petrochemical prices, not with end-demand. The market itself is large but fragmented and slow-growing in real terms — the ~5% headline CAGR is value (price-inflated); underlying volume growth in mature consumer-cleaning is low-single-digit and exposed to private-label trade-down.

Apply the industry-structure lens: surfactants for commodity laundry/dish have no meaningful barrier to entry beyond scale and feedstock access — products are substitutable, the largest customers are bigger than Stepan and several internalize production (the 10-K notes competition “from the internal divisions of larger customers”), and market share is contestable. That is the profile of a bad sub-industry: no captive demand, no proprietary cost advantage, price-led competition. The redeeming portions are the higher-value niches — Crop Productivity (ag adjuvants), Oilfield, Industrial Cleaning, and Tier-2/3 accounts — where formulation expertise, customer qualification, technical service and registration create real switching frictions and price is not the only axis. Stepan’s strategic pivot toward these is the right move, but the core remains commodity.

5.3 Feedstock / oleochemical dynamics — volatility is the structural tax

Stepan’s principal raw materials are “either petroleum-based or plant-based” (10-K). The plant-based side — coconut oil (CNO) and palm-kernel oil (PKO) — is the structural swing factor. PKO is ~48% lauric acid, the preferred feedstock for fatty alcohols and surfactants. These oils are volatile and were recently elevated: PKO averaged ~$1,873/MT in Indonesia in Q4 2025 (+13.3% QoQ) and ~$1,695/MT CFR Houston in mid-2025; CNO spiked toward ~$3,000/t versus PKO ~$2,000/t before the two converged into 2026 (IndexBox/Tridge/ChemAnalyst, 2025-26). Pass-through contracts protect margin dollars over a full cycle, but the timing lag hurts in rising-cost quarters — Stepan absorbs the cost increase before it reprices, compressing reported gross margin precisely when feedstock spikes. Supply is concentrated (SE Asia) and weather/geopolitically exposed, so this volatility is a recurring structural tax, not a one-off. It also distorts the capital cycle: feedstock-driven margin swings can mask the true underlying supply/demand balance.

5.4 Segment 2 — Polymers (~$585M): cyclically depressed, structurally average

Polymers is rigid polyurethane polyols (thermal-insulation rigid foam for construction/energy efficiency), CASE, spray foam, and phthalic anhydride. The end-market is construction-cyclical, and the cycle is currently split: North American demand is firm (+9%; spray foam the fastest sub-segment, ~8%/yr), while European construction is depressed — the −9% European Polymers sales print is the financial fingerprint of weak EU building activity (SCL FY2025 10-K; corroborated by industry sources on EU construction softness). Structurally this is an average industry: real demand growth tied to building codes and energy-efficiency retrofits (a genuine secular tailwind), but Stepan competes against the polyurethane divisions of far larger integrated players (Huntsman, BASF, Dow, Covestro), limiting pricing power. Insulation-driven demand is the better part of this segment; the cyclical trough is real but looks like a cyclical, not structural, impairment.

5.5 Phthalic anhydride — the structurally poor sub-segment

Inside Polymers sits phthalic anhydride (PA), used in polyester/alkyd resins and plasticizers and consumed internally to make polyols. PA is structurally oversupplied: global capacity is ~7M t/yr (more than half in China/Northeast Asia) against ~4M t of 2024 output, with Chinese utilization at only ~57% — the lowest on record — and ~2.5% demand CAGR (Mordor Intelligence / ResourceWise, 2024-25). This is a textbook bad commodity sub-industry: chronic overcapacity, China-led, low utilization, no pricing power. Stepan’s partial internal consumption (PA feeding its own polyols) mitigates the merchant-market exposure, but PA is the weakest structural link in the portfolio.

5.6 Segment 3 — Specialty Products (~$80M): niche, sub-scale, non-core

The smallest segment (food, flavoring, nutritional-supplement and pharmaceutical intermediates) grew ~29% YoY to ~$80M on higher selling prices, but Stepan exited part of its Lipid Nutrition business and impaired the associated goodwill in Q4 2023 (SCL FY2025 10-K). These are higher-margin regulated niches in principle, but at this scale the segment is not a structural driver of the thesis.

5.7 Regulatory landscape — 1,4-dioxane is a genuine structural tailwind

The standout structural positive is regulatory. 1,4-dioxane is an unintended by-product of ethoxylation — the chemistry behind many surfactants, foaming agents and emulsifiers. New York now caps 1,4-dioxane at 1 ppm in household-cleaning and personal-care products (effective 12/31/2023) and 10 ppm in cosmetics; product waivers expired 12/30/2025, and a biennial agency review began 5/1/2025 that could tighten limits further. California is advancing comparable limits under its Safer Consumer Products program (NYSDEC; cosmeticsdesign.com; 3eco.com; cen.acs.org, 2023-26). The economic consequence: brand owners must either reformulate with low-dioxane surfactants or pay up for reduced-dioxane grades — and only producers who have invested to strip dioxane out of ethoxylated surfactants can serve them. Stepan’s 10-K confirms it “made capital expenditures to modify its manufacturing process to reduce 1,4-dioxane content in ethoxylated surfactants,” which “positioned the Company to continue serving existing customers and pursue new market opportunities” (SCL FY2025 10-K). This is a filing-confirmed structural share-shift tailwind favoring compliant, scaled producers — directly relevant to Stepan’s Pasadena investment. It is the clearest example in the portfolio of regulation creating a barrier to entry and captive demand. (The dollar magnitude of incremental volume is management framing only and unquantified.) Other regulation (REACH, TSCA, ethylene-oxide HAP fenceline monitoring, biocide registration) is largely a cost and compliance burden (~$44.9M annual environmental-compliance spend, $9.8M environmental capex in 2025) that raises barriers to entry modestly but does not differentiate Stepan.

5.8 Capital-cycle read — supply is rationalizing

The capital-returns framework asks: is capacity being added or withdrawn, and which way are returns mean-reverting? The evidence points to late-downcycle supply discipline, which is supportive. The broad chemical industry is in a multi-year downturn — Deloitte forecasts sector growth of just ~1.9% (2025) and ~2.0% (2026); global plant-closure announcements roughly doubled in 2025; BASF is cutting toward $2.7B of annual costs by end-2026 (2025 sales −2.9%, earnings −38.8%); Dow posted a $657M loss in January 2026 and announced ~4,500 further job cuts; European capacity utilization sits at ~74.6% (Indian Chemical News/Deloitte; Chemical Week; Alliance Chemical, 2025-26). Stepan itself is a participant in this rationalization: under Project Catalyst it is shutting the Fieldsboro (Hillsborough), NJ site and decommissioning select Surfactant assets at Millsdale, IL and Stalybridge, UK, targeting ~$100M of pre-tax savings against a $70–80M 2026 restructuring charge (SCL FY2025 10-K). This is textbook bust-phase behavior — high-cost capacity being withdrawn after a demand-led trough, the precondition for returns to mean-revert upward. The two distortions that cap the upside: (1) oleochemical feedstock volatility, which can mask the supply/demand signal and re-compress margins in cost-up quarters; and (2) Chinese phthalic-anhydride overcapacity, where the cycle remains stuck in oversupply with no near-term discipline. The surfactant and polyol businesses look mid-to-late in the capital cycle, with returns positioned to recover if cost-out, the dioxane share-shift and an insulation-demand recovery land — but this is a self-help and cyclical-recovery story, not a structurally advantaged one.

5.9 Verdict

Structurally a mixed-to-mediocre industry set — neither clearly good nor uniformly bad — sitting at a supportive point in the capital cycle. Segment by segment:

• Surfactants (core): Structurally mediocre. A large, fragmented, low-real-growth, pass-through market with weak pricing power in the commodity laundry/dish core (no captive demand, contestable share, customers who can self-supply). Redeemed in part by higher-value Crop/Oilfield/Industrial/Tier-2-3 niches and a genuine, filing-confirmed 1,4-dioxane regulatory share-shift tailwind that creates a real barrier favoring scaled compliant producers. Net: a below-average industry with a credible self-help/regulatory path to better-than-commodity economics.
• Polymers: Structurally average, cyclically depressed. Construction-driven; NA firm, Europe in a real trough. Insulation/energy-efficiency demand is a secular positive, but Stepan competes against far larger integrated rivals. A cyclical, not structural, problem.
• Phthalic anhydride: Structurally poor. Chronic global (China-led) overcapacity, ~57% utilization, no pricing power. The weakest link; partly internalized.
• Specialty Products: Niche/non-core. Too small to move the structural verdict.

Capital-cycle call: supply is rationalizing across the sector and within Stepan (Project Catalyst), placing the surfactant/polyol businesses mid-to-late in the capital cycle with returns positioned to mean-revert up from a cyclical low — capped by oleochemical feedstock volatility and Chinese PA overcapacity. The industries are not the source of a durable moat; the better part of any return here will come from Stepan’s self-help (cost-out, mix-shift to niches, dioxane positioning) layered on a cyclical and capital-cycle recovery, not from inherent industry attractiveness.

6. Financial Quality

6.1 Income Statement — Multi-Year (FY2021–2025 + Q1’26)

Consolidated statements of income ($ in thousands unless noted):

*Reported EBITDA = operating income + D&A + other-net; the company’s own FY25/FY24 reconciliation: EBITDA $208.0M (FY25) / $186.8M (FY24). FY21–22 are derived. (Source: FY2025 10-K, Consolidated Statements of Income + MD&A non-GAAP reconciliation; EDGAR XBRL.)

Q1 2026 vs Q1 2025 (10-Q): Net sales $604,509 vs $593,255 (+2%, all FX/price; organic volume flat). Gross profit $64,851 vs $75,463 — gross margin fell to 10.7% from 12.7%. A $65,439 business-restructuring charge drove an operating loss of $(49,622) vs $28,288 income; pre-tax loss $(54,489); tax benefit $13,083; net loss $(41,406), $(1.81)/sh vs $19,711 / $0.86. Adjusted net income $10.3M ($0.45) vs $19.3M ($0.84); adjusted EBITDA $49.6M vs $57.5M (−14%).

The margin-compression story

The decisive feature of this P&L is the collapse from a 2021–22 super-cycle peak to a multi-year trough. Gross margin compressed from 16.9% (2021) → 11.6% (2025) — a ~530 bp erosion — and operating margin fell from 7.5% → 3.4%. Peak net income ($147.2M, 2022) is now less than a third of itself ($46.9M, 2025). Three forces:

1. Volume/demand softness in the commodity core. Reported net-sales “growth” is an accounting artifact of raw-material (oleochemical/petrochemical) pass-through, not volume. FY25 sales rose +$151.8M but +$130.7M was price (pass-through/mix) and only +$16.5M (+1%) was volume; Surfactant volume fell ~2% even as Surfactant sales rose +9% on pass-through. The gross-profit dollars are flat-to-down ($395.8M → $269.9M) because pass-through inflates the denominator without adding margin.
2. Pasadena, TX depreciation step-up. D&A climbed +39% from $90.9M (2021) to $126.0M (2025) as the multi-year Pasadena alkoxylation build (peak capex $301.6M in 2022) moved from construction-in-progress into service. Construction-in-progress fell from $275.0M (FY24) to $112.9M (FY25) as assets were placed in service — i.e., the depreciation drag is still building.
3. Interest expense roll-up. Net interest expense rose from ~$12.1M (2023) to $22.1M (2025) — partly higher debt, partly the roll-off of capitalized interest as Pasadena finished. This is a reported-earnings drag with no incremental cash cost.

6.2 Quality of Earnings — One-Time Items & Normalized Earnings Power

One-time items, three-year tally (from filings)

Net pre-tax one-time impact on operating income: FY2023 +$14.0M of charges (impairment + restructuring); FY2024 essentially clean; FY2025 a net +$9.7M benefit ($15.9M asset-sale gain partly offset by $6.2M goodwill impairment); Q1’26 +$65.4M of charges ($62.4M non-cash impairments: Fieldsboro NJ $43.0M, Millsdale IL $14.3M, Stalybridge UK $5.1M, + $1.8M decommissioning + $1.3M termination). FY2026 full-year restructuring guidance $70–80M. Cash impact of Q1’26 charge <$3M (almost entirely non-cash impairment).

GREEN FLAG: management’s Adjusted EBITDA reconciliation is conservative — it strips OUT the FY25 $15.9M asset-sale gain (does not flatter the metric) while adding back the $6.2M goodwill impairment, yielding Adjusted EBITDA $198.9M (FY25) vs $187.0M (FY24). Reported EBITDA $208.0M actually exceeds adjusted because of the asset-sale gain. This is the rare case where adjusted < reported — a sign the adjustments are not aggressive.

Site detail: the closed NJ surfactant site is Fieldsboro, New Jersey (10-Q Note 16). Decommissioning is at Elwood/Millsdale, IL and Stalybridge, U.K. All restructuring charges sit in the Surfactants segment but are reported on a separate line, so segment Surfactant operating income is not depressed by them.

Net income vs CFO divergence

CFO has run well above net income in 2023–25 (CFO $147.9M vs NI $46.9M in FY25), the normal signature of a depreciation-heavy business at trough earnings — D&A ($126M) is the swing factor, and it is real cash that has already been spent (Pasadena). The exception is FY2021, when CFO ($72.1M) collapsed below NI as the company built ~$140M+ of working capital into the inflation spike; that reversed hard in FY2023 (inventory release +$144.8M of CFO). The pattern is healthy: earnings are not being flattered by accruals; if anything reported earnings understate cash generation because the depreciation step-up is non-cash. No accrual red flag.

Normalized earnings-power bridge (assumption-heavy)

The central question: what does SCL earn mid-cycle, after Pasadena fully ramps and Project Catalyst delivers, before charges? A normalized run-rate, stating every assumption:

Mid-cycle, post-Catalyst-and-Pasadena earnings power is plausibly ~$280–310M adjusted EBITDA and ~$4.50–5.50 EPS — roughly double trough FY25 ($199M / $2.05) but still below the 2021–22 peak ($263–304M EBITDA, $5.96–6.38 EPS). This is the deep-value crux: GAAP earnings are trough-distorted by (a) the cyclical low, (b) the Pasadena depreciation drag not yet matched by Pasadena revenue, © capitalized-interest roll-off, and (d) restructuring charges. The bridge assumes Catalyst savings stick in the P&L (not competed away via price) and that commodity-surfactant volume does not erode structurally further. Neither is proven; the Competitive Position verdict (no moat in the 71%-of-sales Surfactants segment) argues some savings will be passed to customers.

6.3 Cash Flow & Balance Sheet

Free cash flow & dividend coverage

RED FLAG: Through the Pasadena build (FY22–23) the dividend was funded entirely by debt — FCF was deeply negative. With the heavy capex complete, FY24 FCF turned positive (+$39.3M) and just covered the dividend; FY25 FCF ($25.4M) did NOT cover the $35.0M dividend — a ~$10M shortfall, plugged partly by the $26.6M of asset-sale proceeds. The dividend is currently NOT covered by organic FCF. FY25 payout ratio on net income = $35.0M / $46.9M = 75% (and on a loss in Q1’26). On normalized earnings (~$112M NI) the dividend would be a comfortable ~31% payout — so coverage depends on the normalization thesis playing out.

Dividend status: $0.395/qtr ($1.58 annual); 58 consecutive years of increases (Dividend Aristocrat). Management has continued raising through the trough, signaling commitment, but the trough math means the increase is being funded from the balance sheet / asset sales, not current FCF. FY26 capex guide $105–115M (~75–80% maintenance) keeps FCF thin near-term; the $30M Millsdale land sale (closing fall 2026) and Catalyst savings are the bridge to self-funding the dividend.

Balance sheet, leverage, liquidity

Leverage is moderate, not distressed. Net-debt/EBITDA ≈ $494M / $199M adj. ≈ 2.5x at FY25, ticking to ~2.6x at Q1’26 (net debt up on seasonal WC build + the dividend, equity down on the loss). Capital structure: $324M senior unsecured notes (maturities laddered 2026–2033) plus $302.7M drawn under a $350M revolver + $100M delayed-draw term loan, with $126.9M of revolver availability and $4.1M LCs (FY25 10-K). Foreign subsidiaries carry no debt. Note the $285.7M of “current maturities” at FY25 (and $323.3M at Q1’26) is large relative to cash — but the bulk is revolver classification, not a single bullet; the senior-note ladder mitigates refinancing-wall risk. No covenant or liquidity stress is evident.

Pension/OPEB (immaterial): US and UK defined-benefit plans are both overfunded at FY25 — net recognized asset position of ~$0.5M (US) + $2.2M (UK). No funding overhang; not a risk. Operating-lease liabilities $61.4M (Q1’26); no other material off-balance-sheet items identified beyond ordinary environmental/CERCLA contingencies (the company books ~$45M/yr of environmental-compliance cost and carries remediation reserves).

6.4 Returns on Capital — Is SCL Earning Its Cost of Capital?

*Invested capital ≈ net debt + equity. (Source: EDGAR XBRL; FY25 10-K balance sheet & net-debt reconciliation.)

Verdict on returns (decisive): The business is NOT currently earning its cost of capital. Against an estimated ~8–9% WACC, FY2025 after-tax ROIC of ~3.6% and ROE of ~3.9% mean SCL is destroying economic value at the consolidated level — by roughly half its cost of capital. Returns peaked in the 2021–22 super-cycle (ROIC ~8–9%, ROE ~12%), when they merely reached the cost of capital, and have collapsed since. This is the financial fingerprint of a commodity-tilted, low-moat business. The bull case requires returns to mean-revert up toward the cost-of-capital line as Pasadena ramps, Catalyst cuts fixed cost, and the cycle turns — on the normalized ~$112M NI, ROIC would recover to roughly ~6–7% and ROE to ~9%, i.e., approaching but not durably clearing WACC. Even normalized, this is a cost-of-capital business, not a compounder.

6.5 Material-Event Timeline & Insider Read

Material-event timeline (8-K record)

Two themes dominate the 36-month record: (1) a management/board refresh — new CEO (Rojo), a fully new CFO (Velasquez, ex-3M finance-transformation background), a new operator-director (Painter), and a new executive-severance plan (typical alongside a turnaround); and (2) the pivot to self-help/supply-rationalization (Project Catalyst, Feb 2026). The CFO seat churned (full CFO → interim Hinrichsen for ~9 months → Velasquez) — worth flagging but resolved. No litigation, going-concern, auditor-change, or restatement events appear (auditor Deloitte since 2002; unqualified ICFR opinion).

Insider Form 4 read (EDGAR Form 4 corpus, ~2024-01 → 2026-05)

Insider signal = NEUTRAL-to-slightly-soft: Across ~150+ Form 4s in three years there is exactly one open-market purchase (a token 500-share director buy). There is no insider-buying conviction signal — but equally no discretionary insider selling signal: the dispositions are overwhelmingly routine tax-withholding (F) and founding-family estate activity (G/W), not officers dumping stock. The picture is passive: insiders are neither stepping up to buy the trough nor bailing out. For a stock trading below book at a cyclical low, the absence of meaningful insider buying is a mild disappointment to the deep-value case, but it is not a bear tell.

Verdict — Do Economics Improve With Scale? Quality of Earnings?

Do economics improve with scale: NO, not durably — this is a cost-of-capital business at best. Despite ~$2.3B of revenue and the largest North-American merchant-surfactant footprint, consolidated after-tax ROIC is ~3.6% (FY25) against an ~8–9% WACC, and even at the 2021–22 super-cycle peak returns only reached the cost of capital (ROIC ~8–9%, ROE ~12%). Margins compressed ~530 bp off the peak; the dominant 71%-of-sales Surfactants segment is a pass-through, price-taking commodity business whose “growth” is feedstock inflation, not volume. Scale buys regional cost/freight advantage and supply security — not pricing power. Economics do not improve with scale; they are dictated by the chemical capital cycle.

Quality of earnings: HIGH (clean), even as the level of earnings is poor. The accounting is conservative and the one-time items are transparent: management’s Adjusted EBITDA is conservative (strips OUT the FY25 $15.9M asset-sale gain; adjusted < reported), CFO runs above net income (no accrual flattering; trough GAAP EPS understates cash generation owing to the non-cash Pasadena depreciation/interest drag), pension is overfunded (immaterial), and the auditor relationship (Deloitte since 2002) and ICFR are clean. The Q1’26 loss is ~96% non-cash impairment.

Biggest GREEN flags: conservative adjusted metrics; large non-cash depreciation/interest drag that understates normalized earnings; moderate ~2.5x leverage; Pasadena capex complete (FCF inflecting positive); Project Catalyst supply-rationalization with a credible ~$100M savings target.

Biggest RED flags: (1) the dividend is not covered by organic FCF at trough (FY25 FCF $25.4M < $35.0M dividend; covered only with asset-sale proceeds) — sustainable only if normalization lands; (2) returns below WACC — the business currently destroys economic value; (3) no insider buying despite a below-book, cyclical-low setup; (4) the normalized earnings bridge is assumption-laden — it requires Catalyst savings to stick (not be competed away in a no-moat segment) and commodity-surfactant volume to be cyclically, not structurally, depressed.

Net: A clean-accounting, low-return, deeply cyclical specialty/commodity chemical company at a self-help-and-cycle trough. The quality of earnings supports the deep-value normalization narrative (trough GAAP earnings genuinely understate mid-cycle power, ~$4.50–5.50 EPS / ~$280–310M EBITDA), but the returns evidence says this is a cost-of-capital business, not a compounder — and the uncovered dividend is the financial risk that must resolve.

7. Capital Allocation

Capital allocation is the single most consequential lens on Stepan over this cycle, because the company made one very large, multi-year bet — the Pasadena, Texas alkoxylation hub — financed largely with debt, into the teeth of a surfactant/specialty-chemical downcycle, and is now defending a 58-year dividend-increase streak while simultaneously declaring deleveraging the priority and launching a restructuring (Project Catalyst). These objectives are in tension, and the tension is the story.

Five-Year Uses of Cash

Uses-of-cash table (USD millions; EDGAR XBRL):

¹ PaymentsToAcquirePropertyPlantAndEquipment. ² PaymentsOfDividends. ³ PaymentsForRepurchaseOfCommonStock (FY23–25 buybacks effectively nil; $125.1M remained authorized at 3/31/26, none repurchased in Q1’26 — 10-Q). ⁴ NetIncomeLoss.

The CapEx mountain. Stepan’s maintenance/baseline CapEx historically ran ~$80–105M (2017–2020). From 2021–2023 it spent a combined ~$756M, of which roughly $350–400M was the incremental growth bet above a normal-year baseline — overwhelmingly Pasadena. CapEx then dropped back to ~$122M in 2024 and 2025 as Pasadena completed. Operating cash flow in the bet years was below CapEx (2022 OCF $161M vs CapEx $302M), so the growth program was debt-funded. That is the origin of the leverage discussed below.

The Pasadena alkoxylation hub — the defining decision

Announced October 2021 with an original budget of ~$220M and an expected late-2023 startup; flexible capacity of ~75,000 metric tons/year (ethoxylation + propoxylation) on the U.S. Gulf Coast (Stepan PR, 2021-10). Supply-chain disruption, labor shortages and cost inflation pushed both the budget and the schedule: by early 2024 the estimated cost had risen to ~$265M and startup slipped to 2025 (FY24 10-K risk factor; FY23/FY24 disclosures). The facility started production in April 2025 (FY25 10-K). Management’s framing: ramp to ~80% utilization in 2026, full utilization in 2027.

Does it earn its cost of capital? This is unproven and currently dilutive. In 2025 the only visible Pasadena P&L effect was negative: startup costs reduced gross profit (cited as part of a $19.8M gross-profit headwind in Surfactants; ~$8.6M pre-tax drag in Q3’25 alone), and lower capitalized interest (the plant left construction) raised reported interest expense. The asset now sits in the rate base earning nothing close to a return while the company carries the debt that built it. The bull case — that a flexible, modern, scale alkoxylation asset on the Gulf Coast (feedstock-advantaged, near customers) generates high-return specialty volumes through 2027 — is plausible but entirely forward-dated. A ~$265M project that came in ~20% over budget, ~18 months late, and started up into a demand trough is, on the evidence to date, a capital-allocation decision that has destroyed value; the verdict on whether it ultimately clears its cost of capital cannot be rendered until the 2026–2027 ramp produces actual segment economics. Hold management to the 80%/full-utilization milestones.

M&A and divestitures

No material acquisitions in the window. The recent activity is the reverse — footprint pruning, consistent with a “focus on core” posture:

• Stepan Philippines Quaternaries, Inc. (SPQI), Bauan, Batangas — manufacturing assets sold Q4 2025 to Masurf, Inc. (a Musim Mas subsidiary), with a tolling agreement to keep serving SE-Asia customers; pre-tax gain ~$5.1M (FY25 10-K, Note 20).
• Lake Providence, Louisiana manufacturing assets sold Q4 2025; pre-tax gain ~$10.8M (FY25 10-K, Note 20). Combined Q4’25 asset-sale gains ~$15.9M.
• Millsdale (Elwood, IL) land parcel — Purchase & Sale Agreement to sell a non-operating parcel for $30.0M, expected to close 2H 2026 (Q1’26 10-Q).

These are small, sensible disposals of sub-scale/non-core assets at modest gains, and the $30M land sale is opportunistic cash for deleveraging. They do not move the thesis on their own but signal a management shift from build-everywhere expansion toward consolidation into the (now larger) core network.

Dividend vs. deleveraging — the central tension

Quarterly dividend $0.395/share = ~$8.96M/quarter (Q1’26 10-Q), ~$35–36M annualized; 58 consecutive years of increases (latest raise ~2.6%); yield ~2.9–3.1%. Cash dividends paid grew every year: $28.1M (2021) → $35.0M (2025).

The aristocrat streak is now being defended against thin free cash flow. In 2025, OCF $147.9M − CapEx $122.5M = ~$25M of free cash flow, below the ~$35M dividend. 2024 was similar (FCF ~$39M vs dividend $34M). With net income compressed to ~$47M (a GAAP payout ratio ~75%), the dividend is being funded partly from the balance sheet, not from surplus FCF. This is sustainable only because (a) CapEx has normalized off the Pasadena peak, (b) Project Catalyst is meant to add ~$100M of pre-tax savings, and © the $30M land sale and divestiture proceeds provide one-time cash. The streak is a constraint on capital allocation, not a free good: every dollar of dividend in 2024–2025 is a dollar not used to deleverage, at a moment when management has named deleveraging the priority. So far the board has chosen to protect the streak with a token raise rather than freeze it — a defensible choice given the small absolute dollars, but one that should be watched if the downcycle persists into 2027.

Leverage and balance sheet

Total debt rose to fund Pasadena. Balance-sheet debt ~$625–627M at 12/31/24 and 12/31/25; cash ~$99.7M (FY24) and ~$132.7M (FY25), implying net debt ~$494M at YE2025 (~2.5–2.7x EBITDA on ~$206M FY25 EBITDA). At 3/31/26 debt ~$651.7M, cash ~$140.8M → net debt ~$511M. Long-term debt has been trending down from a 2022–23 peak (LTD-noncurrent $438M mid-2023 → $341M YE2025). Deleveraging is the stated priority. Leverage is elevated but not distressed for a chemical company with hard assets and a covenant-light profile; the risk is duration — if the downcycle persists, the combination of a defended dividend, restructuring cash outflows, and ramp-stage Pasadena slows deleveraging materially.

Share issuance / buybacks / SBC

Buybacks were modest historically ($17–25M/yr 2021–22) and effectively paused in 2023–2025; $125.1M remained authorized at 3/31/26 with none repurchased in Q1’26 (Q1’26 10-Q). Stock-based compensation is small and not dilutive in scale: ~$5.3–6.0M/yr (2023–2025), down from ~$13.9M in 2022. Share count is stable; this is not a dilution story. Pausing buybacks while leverage is elevated is the correct call; capital is rightly prioritized to debt paydown and the dividend over repurchases.

Incentive Alignment — what the proxy actually pays for

2026 proxy (FY2025 comp). Two programs:

2025 payout outcome. Net Income came in at $46.9M, below the $50M threshold → 0% payout on the 50%-weighted Net Income objective; EBITDA $205.9M (>$190M threshold) paid 14.3%; FCF $27.1M (>$20M) paid 7.8%; Safety paid 2.5% at 50%-of-target. The plan worked as designed — weak profitability produced a low bonus. CEO Rojo’s total 2025 comp was $4.33M (salary $940k, no annual cash bonus reported beyond the formula, $2.28M stock, $0.80M option/PSU, $230k non-equity incentive).

CEO must hold shares worth 5× base salary; other officers 2.5×. ROIC is an explicit LTI gate. NOPAT/invested-capital ROIC definition disclosed.

Alignment is above-average for the sector. Critically, the plan does not reward volume or sales growth that would tempt a commodity-chemical management to chase share at value-destroying prices — the classic failure mode. It pays for net income, EBITDA, free cash flow, and ROIC — exactly the right surfaces, and the ROIC modifier is the single most important alignment feature given the Pasadena bet (it ties LTI value to whether that ~$265M asset earns a return). The honest weakness: the program is heavily absolute (net-income-anchored), with no relative-TSR metric, so it can pay for a cyclical updraft the management did not create — and conversely punishes a cyclical trough (as in 2025) regardless of relative execution. Still, an incentive system that gates pay on ROIC and FCF, with a 5× CEO ownership requirement, is well-constructed.

Insider ownership

2026 proxy beneficial ownership: F. Quinn Stepan, Jr. (Chairman; CEO until April 2022) owns 961,674 shares ≈ 4.6%; Richard F. Stepan 255,700; CEO Luis E. Rojo 80,739; CFO Ruben Velasquez 4,110 (new); all directors & executive officers 1,492,974 ≈ 6.6% of 22.69M shares outstanding. The Stepan family legacy stake plus family board/management presence (Richard Stepan is an executive officer; Rojo is non-independent partly on that basis) means founder-family interests remain materially aligned with outside holders — skin in the game, though not a controlling block.

Verdict: Mixed, leaning cautious — a well-aligned management that made one large, ill-timed capital bet whose payoff is unproven. The incentive system is genuinely good (ROIC-gated LTI, FCF in the bonus, no volume-chasing metric, 5× CEO ownership, ~6.6% insider stake) and the recent disposals and buyback pause are disciplined. But capital allocation is judged on outcomes, and the outcome that dominates this cycle — Pasadena — came in ~20% over budget, ~18 months late, and started up into a demand trough, and is today a drag on earnings and cash. Compounding that, the board is funding a 58-year dividend streak out of free cash flow that in 2024–2025 was below the dividend, while simultaneously calling deleveraging the priority. The thesis on capital allocation therefore hinges entirely on the 2026–2027 Pasadena ramp and Project Catalyst savings converting into the ROIC the LTI plan demands. Management has the right scorecard; it has not yet posted the score.

8. Major Changes & Headwinds — Last Two Years

The last two years are a cluster of large, mostly self-inflicted-or-cyclical changes landing simultaneously: a major plant startup, a leadership turnover, a structural restructuring, asset sales, and a deep commodity-chemical downcycle with raw-material and geopolitical overlays.

1. Pasadena startup (April 2025). Covered above. Net effect to date: negative — startup costs and lost capitalized interest hit 2025 earnings; the offsetting volume/margin benefit is a 2026–2027 promise. Strategically it modernizes and scales Stepan’s alkoxylation franchise; financially it has yet to pay.

2. Project Catalyst (announced Feb 2026). Board approved 2026-02-20; targets ~$100M pre-tax savings over two years (~60% in 2026). Closes Fieldsboro, NJ; decommissions select assets at Millsdale (Elwood, IL) and Stalybridge, UK by mid-2026; consolidates volume into the existing (now Pasadena-anchored) network to lift utilization and cut fixed cost. Restructuring charges $70–80M in 2026 (cash $29–44M, non-cash $58–62M); ~$52–62M recognized in Q1’26 (the 10-Q booked $65.4M of business restructuring, driving a $49.6M operating loss and a $41.4M net loss for the quarter). Paired with the $30M Millsdale land sale (2H’26). Strategically coherent and overdue — pruning high-cost legacy NJ/UK surfactant assets after building modern Gulf Coast capacity is the right sequencing, and a $100M run-rate save is large versus ~$47M of FY25 net income. Near-term it is a real cash and GAAP hit; the risk is execution (will the $100M materialize, and on schedule?) and customer-supply continuity during consolidation. Net: a forward-positive change with meaningful near-term cost and execution risk — verdict tilts positive if delivered.

3. 2025 divestitures. SPQI Philippines and Lake Providence (above). Net: mildly positive — sheds sub-scale assets, books small gains, raises cash, focuses the portfolio.

4. Leadership and board changes — who runs the company now.

• CEO: Luis E. Rojo, President & CEO since October 29, 2024 — promoted from CFO. He is non-independent (family ties).
• Former CEO Scott R. Behrens served April 25, 2022 → October 29, 2024, then departed.
• CFO: Ruben Velasquez, VP & CFO since July 15, 2025 — an external hire replacing interim/VP-Finance Luke Hinrichsen.
• F. Quinn Stepan, Jr. remains Chairman (was CEO until April 2022).
• Board additions include Corning F. Painter (CEO of Orion S.A.; director since 2025) and Lorinda A. Burgess (ex-Medtronic Americas CFO).

A finance-led management now runs Stepan: a CFO-turned-CEO and a new external CFO, both installed during the downcycle/Pasadena ramp. That profile fits the current agenda — deleveraging, cost-out (Catalyst), and disciplined ROIC. The flip side: this team has a short track record at the top through a full cycle, and the CEO transition overlapping the Pasadena startup means accountability for the overrun spans both the prior and current CEO. The Painter board addition brings sitting-chemical-CEO judgment, a governance positive. Net: neutral-to-positive — right skill set for the moment, unproven over a cycle.

5. Commodity-chemical downcycle (FY23–FY26). Net income collapsed from ~$147M (2022) to ~$40M (2023), ~$50M (2024), ~$47M (2025) — a structural earnings reset, not a one-off. Surfactant volumes soft; pricing pressure across the industry. This is the dominant headwind and it is largely exogenous (global surfactant oversupply, destocking, weak end-demand). It is what turned the Pasadena bet from “well-timed expansion” into “capacity added into a trough,” and it is why FCF no longer comfortably covers the dividend. Negative, and the swing variable for the whole thesis.

6. Oleochemical raw-material cost spikes. FY25 cited higher oleochemical raw-material costs (coconut/palm-kernel-derived feedstocks, CNO/PKO) as a gross-profit headwind alongside Pasadena startup. Margin squeeze from input inflation that Stepan cannot fully pass through in a soft-demand market — a classic downcycle margin pincer. Negative.

7. Europe construction weakness. Polymers (~25% of sales) makes polyurethane polyols for rigid foam thermal insulation used in construction; European construction softness pressures this end-market (FY25 10-K). Cyclical demand drag on the highest-margin segment; tied to European building activity and rates. Negative, cyclical.

8. Tariffs / geopolitical energy shock. 2025–2026 disclosures flag global trade-policy/tariff risk and broader macro uncertainty; 2026 commentary references energy-price and geopolitical (Iran-region/energy) shocks as cost-inflation risks. Raises feedstock/energy cost volatility and trade friction for a globally-sourced manufacturer; a watch-item rather than a quantified hit in the filings to date. Negative bias, uncertain magnitude.

Verdict: On balance the last two years WEAKEN the near-term thesis but set up a potential inflection. The cluster is dominated by negatives that are largely cyclical/exogenous (downcycle, oleochemical inflation, European construction, tariffs/energy) layered on one self-inflicted strategic strain (the over-budget, late Pasadena startup into a trough, plus a dividend now exceeding FCF). The genuinely positive changes — Project Catalyst ($100M cost-out), the disposals, the modern Pasadena asset, and a finance-disciplined management — are all forward-dated promises rather than booked results. The thesis is weaker today than two years ago; whether it re-strengthens depends entirely on three 2026–2027 deliverables converting from plan to fact: the Pasadena ramp to full utilization, the full Catalyst savings, and a cyclical recovery in surfactant demand. Until then, the changes are a net headwind with embedded optionality.

9. Risk Analysis (Risk Matrix)

Risks are scored on likelihood (Low/Med/High) and impact (Low/Med/High) to the thesis, each with its evidence basis. The dominant risks are the mirror image of the bull case: the levers that drive normalization are precisely what can fail.

Net risk read: the thesis is levered to self-help execution in a no-moat industry, so the highest-impact risks (1, 2, 3, 8) all key off the same question — does normalization stick? Downside is real (bear pierces book) but a catastrophic loss is unlikely given asset backing and moderate leverage. This is a “wide-but-survivable” risk profile, appropriate to a deep-cyclical value name.

10. Valuation

Embedded-expectations + bear/base/bull scenario analysis. No price target, no recommendation — the body discusses valuation only as the expectations embedded in the current price and the assumptions each scenario requires. Market data as of 2026-06-05 close, reconciled to SEC filings (FY2025 10-K; Q1’26 10-Q).

10.1 The market data, reconciled

Two EV conventions matter. A gross-debt basis ($713M debt incl. operating leases) gives EV ~$1.74B; on the company’s own net-debt definition (~$511M) EV is ~$1.68B. Both are used below and the basis is flagged for each ratio; the conclusions are not sensitive to the ~$60M difference. Trailing-twelve-month EBITDA is distorted by the Q1’26 $65.4M restructuring charge (which produced a GAAP operating loss); TTM GAAP EPS is therefore negative (~−$0.62), and trailing P/E is not meaningful. The clean denominators are FY2025 adjusted EBITDA ($198.9M) and forward consensus EPS (~$3.9), not TTM GAAP.

10.2 Multiples — the full table (trough, TTM, and normalized)

The central analytical problem in valuing SCL is denominator choice: every trailing multiple is computed on cyclical-trough, restructuring-distorted earnings, so the stock looks expensive on trailing metrics (EV/EBITDA ~8–9x on trough EBITDA, no trailing P/E) yet cheap on book and on normalized earnings (P/B 0.94x, ~10x normalized P/E). The table below shows all three lenses; the disagreement between them is the thesis.

Own-history percentiles place SCL at the cheapest ~7–8% of its own decade on book and sales (P/B 7.9th, P/S 6.4th, composite 7.2nd percentile of the trailing ~10-year range). Measured against itself, the stock is unambiguously at a decade-trough valuation. That is necessary but not sufficient for “cheap” — a business whose through-cycle returns have structurally deteriorated deserves a lower multiple than history, so own-history percentiles must be cross-checked against the returns evidence (section 6.4).

Peer cross-read

The peer set is itself near a cyclical low, so peer EV/EBITDA is inflated by trough denominators (HUN 19x, WLK 21.6x are not “rich” — their EBITDA is collapsed). The cleaner reads are forward P/E (peer median ~9–13x) and P/S (~0.5–0.6x). On forward P/E (~13x) SCL sits roughly in line to slightly rich versus levered commodity peers (CE 7.7x, CC 9.1x, KOP 8.7x) and in line with the best specialty comp (IOSP 13.2x). On P/S (0.50x) SCL is at the bottom of the set — consistent with its thin ~11% gross margin (low margin → low justified P/S). The single most informative peer is Innospec (IOSP): a genuine specialty-surfactant peer trading at ~13x forward / 1.11x sales / 9.4x EV/EBITDA — i.e., the re-rating ceiling if SCL’s mix-shift-to-specialty thesis actually lands. SCL trades at <half IOSP’s P/S because the market does not yet credit SCL with specialty-grade margins. That gap is the bull-case prize and the bear-case warning simultaneously.

10.3 Embedded-expectations analysis — what is the market underwriting?

At $51.28 / EV ~$1.68–1.74B, reverse-engineer the mid-cycle economics the price implies and test them against the returns evidence.

What EBITDA does the EV imply at peer multiples?

Holding EV at ~$1.68B (filed net-debt basis), the implied EBITDA at a range of multiples is:

The market is underwriting a partial normalization, not a full one and not a permanent trough. Read it from both ends:

• If you believe SCL is a pure commodity processor deserving ~6–7x, the current EV implies the market expects EBITDA to recover to ~$240–280M — i.e., most of the way to the normalized ~$280–310M. On that read, the market is already pricing the normalization and there is little embedded upside; the bull case is “in the price.”
• If you believe SCL deserves a specialty-tilted ~8–9x (IOSP-like), the current EV implies the market is paying for only ~$186–209M of EBITDA — barely above the FY25 trough ($199M adj). On that read, the market is pricing a near-permanent trough with no re-rating, and any normalization + multiple expansion is unpriced upside.

The truth sits between: the market is paying ~8x trough-ish EBITDA, which equals ~6x normalized EBITDA. That is the signature of a stock priced as a cyclical commodity name that the market expects to partially recover but does not trust to re-rate to specialty multiples. The embedded expectation is “returns mean-revert toward — but not durably through — the cost of capital, and the multiple stays commodity-low.”

Cross-check via ROIC / book value

SCL trades at P/B 0.94x — below book. For an asset-heavy business, sub-1.0x P/B is the market’s verdict that ROIC < cost of capital on a through-cycle basis — the price says invested capital is worth slightly less than its carrying value because it does not earn its keep. This is internally consistent with the returns evidence: FY25 after-tax ROIC ~3.6% vs ~8–9% WACC; even normalized ROIC only recovers to ~6–7% — approaching but not durably clearing WACC. A business that earns ~6–7% against an ~8–9% WACC mid-cycle should trade at a modest discount to book. So the below-book price is not primarily an anomaly — it is a rational discount for sub-WACC returns (section 10.5 tests whether asset value offers a floor below that).

What must be true to justify the price (embedded base case)

At ~$51, the market is implicitly underwriting roughly:

• Mid-cycle adjusted EBITDA recovering to ~$240–280M (Catalyst + partial Pasadena ramp + modest cyclical recovery), short of the bull ~$310M+;
• Through-cycle EPS ~$3.5–4.5 (between consensus forward ~$3.9 and the normalized ~$4.90);
• ROIC recovering to ~6% — below WACC, hence the sustained sub-book multiple;
• The dividend held (not cut), self-funded once FCF normalizes;
• No specialty re-rating — the multiple stays commodity-cyclical (~7–8x EV/EBITDA, ~12–13x P/E).

The variant-perception question (section 11) is whether reality lands above this embedded base (Catalyst sticks + Pasadena specialty volumes + cycle turn → $310M+ EBITDA and a re-rate toward/above book) or below it (Catalyst savings competed away in the no-moat core, structural commodity-surfactant erosion, dividend cut → returns stay at trough and the discount to book widens).

10.4 Scenario analysis — Bear / Base / Bull

Each scenario states its operating drivers (volume, margin, Catalyst realization, Pasadena utilization, feedstock, leverage) and an applied multiple, then derives an equity-value-per-share range (EV = EBITDA × multiple; equity = EV − ~$511M net debt; ÷22.71M shares). These are scenario outputs, NOT a price target — the spread between them is the point.

The scenario fan is wide and asymmetric in both directions — characteristic of a deep-cyclical at a trough with a self-help overlay. The bear ($25–38) is anchored below tangible book ($49/sh) — it requires the market to conclude the assets earn sub-WACC permanently and to apply a distressed multiple to a cut-dividend commodity name; book value does not fully floor it because impaired/closing surfactant assets (Q1’26 $62M write-downs) prove carrying value is not recoverable in a true bear. The base ($61–73) sits above both the current price and book — it embeds the Catalyst/Pasadena normalization, at an unchanged commodity multiple. The bull ($87–112) requires both full operational delivery and a multiple re-rate toward specialty (IOSP-like) — two independent things, hence lower probability than its range alone suggests.

The current $51 sits at the low end of the base case / high end of a soft scenario — i.e., the market is pricing modest normalization but explicitly withholding credit for (a) the full Catalyst $100M, (b) a specialty re-rate, and © a cyclical cycle-turn. That is the embedded-expectations crux restated as scenarios.

10.5 The below-book angle — justified discount or hidden asset value?

Is P/B 0.94x a rational discount for sub-WACC returns, or an anomaly where asset/replacement value exceeds the ~$1.165B market cap? Both are partly true; the discount is mostly justified, with a thin asset-value cushion underneath.

(a) Justified-discount case (dominant). Through-cycle ROIC ~3.6% trough, ~6–7% normalized, vs ~8–9% WACC. An earnings-power value (EPV) cross-check makes this concrete:

• Trough EPV: normalized-trough NOPAT ~$60M ÷ ~8.5% WACC ≈ ~$700M enterprise EPV − $511M net debt ≈ ~$190M equity (~$8/sh). Far below the market cap — i.e., on trough earnings capitalized in perpetuity, the equity is worth a fraction of $1.165B. This is why the stock is not obviously cheap on current earnings.
• Normalized EPV: normalized NOPAT ~$112M ÷ ~8.5% ≈ ~$1.32B enterprise − $511M ≈ ~$810M equity (~$36/sh). Still below the current $1.165B market cap and below book.
• Reconciliation: the market cap ($1.165B) exceeds even the normalized EPV (~$810M) — meaning the price already embeds growth/recovery value above steady-state normalized earnings power (Pasadena ramp, cycle turn, Catalyst upside). When price > EPV and there is no franchise (confirmed: no moat, ROIC < WACC), the gap is unearned growth optimism. On a pure EPV basis the stock is not a deep-value bargain — it is fully-to-richly priced on steady-state economics and is being bought on the recovery option.

(b) Asset-value / hidden-value case (thin cushion). The $30M Millsdale land sale (P&S signed, closes 2H’26) on a non-operating parcel hints that carrying value understates some real-estate/land value — book PP&E is at historical cost, and a >50-year-old footprint (Millsdale dates to the 1950s) may carry land at trivial cost basis. This is real but small — one $30M parcel against a $1.165B cap is ~2.5%; it does not convert a fully-priced-on-EPV stock into an asset-value bargain, but it does provide a modest deleveraging cash bridge and signals optionality in the land bank. Replacement cost of the Pasadena asset (~$265M spent) plus the broader network arguably exceeds book, but replacement value only matters if a rational acquirer would pay it — and in an over-supplied commodity (the Q1’26 impairments prove the opposite), replacement cost is not a reliable floor. Net: tangible book (~$49/sh) is a soft floor, not a hard one — the impairments show some of that book is not recoverable, so the true downside (bear $25–38) can pierce it.

Verdict on below-book: Mostly a justified discount for structurally sub-WACC returns, not a clean anomaly. EPV on steady-state economics is below the current market cap; the price already embeds recovery optionality. The land-sale and replacement-cost angles provide a thin cushion and deleveraging optionality, not a margin of safety. The deep-value case rests not on hidden assets but entirely on the normalization/recovery thesis flagged above as unproven.

10.6 The single most important valuation swing factor

Project Catalyst realization × the multiple it earns. Everything pivots on one question: does the ~$100M Catalyst savings (+Pasadena specialty ramp) (a) actually reach the P&L and (b) earn a specialty multiple — or © get competed away in the no-moat commodity core at an unchanged commodity multiple? This single factor moves normalized EBITDA from ~$200M (bear) to ~$310M+ (bull) — a ~$110M swing — and swings the applied multiple from 6x to 9x. Combined, those two effects are the difference between the ~$25–38 bear and the ~$87–112 bull. Feedstock (CNO/PKO) volatility is the second-order swing (it can mask the signal for several quarters), and the dividend decision is the financial-risk swing (a cut would confirm the bear and trigger de-rating), but Catalyst-sticking-and-re-rating is the master variable.

Verdict — What is the market pricing?

The market is pricing SCL as a deep-cyclical commodity chemical at a decade-trough valuation (P/B 0.94x, 6.4th–7.9th own-history percentile), underwriting a partial recovery but explicitly withholding credit for the full self-help program, a specialty re-rate, and a cycle turn. Decomposed:

1. On trailing/trough metrics the stock looks fair-to-rich (EV/EBITDA ~8–9x on trough EBITDA, no trailing P/E, EPV below market cap) — it is not a statistically cheap stock on current earnings.
2. On book and normalized earnings it looks cheap (0.94x book, ~10x normalized P/E, ~10–13% normalized FCF yield) — if normalization lands.
3. The reconciliation: at ~$51 the price equals ~8x trough EBITDA = ~6x normalized EBITDA = ~$240–280M of implied mid-cycle EBITDA. The market expects returns to mean-revert toward but not durably through the ~8–9% WACC, and the multiple to stay commodity-low (no specialty re-rate). That embedded base case is consistent with the body’s verdict: a clean-accounting, sub-WACC, no-moat commodity processor with a credible — but unproven — self-help-and-cycle recovery option.
4. The below-book price is mostly a justified discount for structurally sub-WACC returns (confirmed by EPV < market cap), not a hidden-asset anomaly; tangible book (~$49/sh) is a soft floor that the bear case (~$25–38, pierced by impairments) can break.
5. Scenario fan ~$25–38 (bear) / ~$61–73 (base) / ~$87–112 (bull), with the current $51 at the low end of base — wide and two-sided, with the asymmetry governed by the single master variable: whether Project Catalyst + Pasadena specialty volumes reach the P&L and earn a re-rating, or get competed away in the no-moat core at an unchanged commodity multiple.

No price target, no recommendation — the foregoing is the range of values implied by explicit operating and multiple assumptions, and the expectations embedded in the current price.

11. Variant Perception

Consensus view. Sell-side and the tape treat SCL as a beaten-up, fairly-valued small-cap commodity chemical at a cyclical low — forward P/E ~13×, a third-party consensus target around $75 (color only, not adopted here), 2.5% short interest (no crowded short), 87% institutional ownership. The consensus is neither euphoric nor capitulatory: it credits a partial recovery (Catalyst + Pasadena + cycle) but applies an unchanged commodity multiple and withholds credit for a specialty re-rating. The stock is under-followed (low volume ~157k shares/day, thin analyst coverage), which is itself why a variant view can exist.

The strongest bull case. Trough GAAP earnings ($2.05 EPS, −$1.81 Q1’26) massively understate normalized power. Three independent self-help levers — $100M Catalyst savings, the Pasadena specialty/low-dioxane ramp, and deleveraging/asset sales — stack on top of an eventual cyclical recovery in European construction and consumer surfactants. If even two of three land, normalized EBITDA roughly doubles to ~$280–310M and EPS to ~$4.50–5.50; on an unchanged ~8× multiple that is a ~$75–90 stock, and with a partial specialty re-rate toward Innospec (the one true specialty peer at ~13× forward / 1.1× sales vs SCL’s 0.5×), ~$90–112. You are paid 3% to wait via a 58-year dividend aristocrat, downside is buffered by below-book/tangible-asset value, and the industry is rationalizing supply (a favorable capital cycle) — high returns will follow the capacity cuts.

The strongest bear case. This is a no-moat commodity processor that has never durably earned its cost of capital — peak ROIC only reached ~8–9%, trough is ~3.6%, normalized is ~6–7% (still sub-WACC). An EPV on steady-state earnings (~$36/sh equity) is below the current price, so you are paying for a recovery that, in a business with no pricing power, cannot be retained: Catalyst cost-outs get competed away as price in the 71%-of-sales commodity Surfactants core, where volume is already declining (−2% FY25, −2% Q1’26) on private-label trade-down and customer self-supply. The Pasadena bet is over-budget, late, and unproven. The dividend is uncovered by organic FCF and is being defended from the balance sheet and asset sales — a cut would shatter the one thing holding the shareholder base and de-rate the stock through tangible book (~$49), which the Q1’26 impairments prove is a soft floor. “Normalized” may simply be “still sub-WACC, permanently.”

The 3–5 assumptions that matter most, and what would falsify each:

Variant read: the evidence tilts bear-of-consensus on business quality (no moat, sub-WACC, uncovered dividend) but the price already embeds much of that. The genuine variant-perception opportunity is timing and entry, not direction: the recovery option is real and partly free below tangible book, but at $51 you pay for it before it is proven. The disagreement worth having with the market is not “will it recover” (the market half-believes it will) but “what multiple will the recovery earn” — and on a no-moat core, the honest answer is commodity, which caps the bull.

12. Fact vs. Interpretation Table

13. Open Questions

1. Are Project Catalyst savings sticking in margin, or leaking to price? The single most important unknown; resolvable only by watching sequential gross margin through 2026 — not by management assertion.
2. Is the Surfactant volume decline cyclical or structural? Two consecutive −2% volume quarters (FY25, Q1’26) could be weather/timing (management’s claim) or secular private-label/self-supply erosion. Decisive for the normalization thesis.
3. What are the actual revenue and returns of the “strategic” niches (Crop Productivity, Oilfield, Industrial Cleaning, Tier-2/3)? Management cites double-digit volume growth, but filings do not break these out — unverifiable today.
4. Will Pasadena demonstrably lift consolidated margin/ROIC, or merely offset legacy commodity erosion (net repositioning, not net accretion)? No filing evidence of uplift yet.
5. Is the dividend defensible through 2026–27 without further asset sales? Coverage depends entirely on normalization; the board has not signaled, and the streak creates a behavioral commitment that could outlast the economics.
6. What is the precise near-term debt-maturity schedule (the large “current maturities” line is mostly revolver classification, but the note ladder 2026–33 should be confirmed against covenant headroom)?
7. Why no insider buying at a below-book, decade-trough valuation if management believes the normalization thesis? Passivity is a mild dissonance with the bull case.

14. What Must Be True (Bull and Bear, each with a falsification test)

For the BULL case to be right, the following must hold:

1. Project Catalyst delivers ~$70–100M of net savings that reach the P&L and are retained (not competed away) → Falsified if consolidated gross margin does not expand sequentially through Q2–Q4 2026 despite management reporting savings “delivered.”
2. Surfactant volume decline is cyclical and reverses → Falsified if organic Surfactant volume is negative for a third and fourth consecutive quarter on demand (not weather/timing) grounds.
3. Pasadena reaches full utilization with a specialty mix-shift that lifts segment margin → Falsified if Surfactant operating margin does not rise above ~5–6% as utilization climbs in 2026–27.
4. Normalized EBITDA reaches ~$280–310M and the dividend self-funds → Falsified if FY26–27 FCF fails to cover the dividend and the board cuts or freezes it.
5. The market grants at least a partial re-rating toward specialty multiples → Falsified if the multiple stays pinned at ~6–8× EV/EBITDA even as normalized EBITDA recovers.

For the BEAR case to be right, the following must hold:

1. The 71%-of-sales commodity Surfactants core has no pricing power, so cost-outs become price concessions → Falsified if gross margin expands and holds while volume is stable-to-up (savings retained).
2. Surfactant volume erosion is structural (private label, customer self-supply, low-cost imports) → Falsified if volume inflects positive on genuine demand for two-plus quarters.
3. “Normalized” returns remain below WACC (~6–7% < ~8–9%), so a sub-book multiple is permanent → Falsified if through-cycle ROIC demonstrably reaches/exceeds ~8–9%.
4. The dividend is cut, removing the floor and forcing out the aristocrat shareholder base → Falsified if the dividend is maintained and covered by normalized FCF by 2027.

Synthesis: Bull and bear pivot on the same fact pattern observed over the next 2–4 quarters — the direction of gross margin and Surfactant volume as Catalyst savings and Pasadena volumes are supposed to arrive. That makes this an unusually testable thesis: the falsification signals are concrete, near-term, and disclosed quarterly. The disciplined posture is to demand either a lower entry price (margin of safety to tangible book) or early confirmation of margin expansion before paying up.

15. Source Appendix

A full, categorized source list is provided in Appendix B below. Primary sources include Stepan Company SEC filings (FY2023–FY2025 10-Ks; FY2023–Q1’26 10-Qs; 8-Ks including the Project Catalyst Item 2.05; DEF 14A proxies 2024–2026; Form 3/4/5 insider filings), EDGAR XBRL financial data, Q4-2025/Q1-2026/Q1-2025 earnings-call transcripts, and third-party market/industry data and peer financials.

APPENDIX A — Diligence Questionnaire

A structured Q&A that supports — and does not replace — the body above (sections 1–15); it is grounded in the same evidence and section drafts, not separate research. Labels: Fact / Interpretation / Assumption / Open Question. No price target or BUY/SELL appears anywhere except the “Claude’s Take” block.

General

What thoughtful questions have other investors asked about this company?

Drawn from the recent earnings-call Q&A (Q4’25, Q1’26) and the analytical tension in the filings, the questions that matter most are:

The unifying investor question is the cyclical-vs-structural one — is depressed profitability a trough to be normalized (self-help + cycle turn) or a permanent reset in commodity surfactants? Every other question is a sub-question of that.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low?

A cyclical low. Net income fell from $147.2M (2022 super-cycle peak) to $40.2M (2023), $50.4M (2024), $46.9M (2025); Q1’26 was a GAAP loss of -$41.4M (-$1.81) on a $65.4M restructuring charge (adjusted NI $10.3M / $0.45). Gross margin compressed ~530bp from the 2021 peak (16.9% to ~11.6% FY25). After-tax ROIC sits at ~3.6% and ROE ~3.9%, both far below an ~8–9% WACC — the financial signature of a trough, not a peak. Normalized earnings power is roughly 2x trough (~$280–310M adjusted EBITDA, ~$4.50–5.50 EPS) if Project Catalyst savings and the Pasadena ramp land — but still below the 2021–22 peak ($5.96–6.38 EPS).

Are earnings driven by the external environment or internal actions?

Both, currently dominated by external drags with internal self-help layered on. External (and dominant): the multi-year global commodity-chemical downcycle, soft surfactant volumes, oleochemical (CNO/PKO) feedstock inflation, and weak European construction. Internal (negative near-term, positive optionality): the Pasadena startup drag (higher depreciation, lower capitalized interest) and the Project Catalyst restructuring charge are internal choices depressing reported earnings now, but they are intended to lift normalized earnings later. The recovery thesis depends on internal actions (Catalyst cost-out, Pasadena ramp, mix-shift) plus an external cyclical turn — neither alone is sufficient.

How stable are revenues?

Headline revenue is volatile but misleadingly so — it swings with feedstock prices, not demand, because most contracts are raw-material pass-through. FY25 sales +7% was only +1% real volume (+2% organic ex-divestiture); the rest was passing higher feedstock costs through. Surfactant “sales +9%” in FY25 masked a 2% volume decline. Underlying volume is the stable-but-low metric (low-single-digit, lumpy); reported dollar revenue is feedstock-driven and unstable. Demand is recurring/consumable (chemicals consumed in customers’ production) but transactional — no long-term contracts or install-base lock-in.

Outlook for products/services?

Mixed by segment. Surfactants (71% of sales) — mature, low-real-growth commodity core with differentiated niches (crop, oilfield, industrial cleaning, low-1,4-dioxane). Polymers (25%) — construction-cyclical; NA firm/spray-foam growing ~8%/yr, Europe in a real trough; phthalic anhydride structurally oversupplied. Specialty/MCT (3.5%) — the genuine growth engine (+15% volume FY25, +30% Q1’26, ~31% op margin) but too small to move the consolidated needle quickly.

How big will this market be — growing, shrinking, domestic or international?

Global surfactants ~$47–50B (2025), ~5% value CAGR (partly feedstock-inflated; real volume growth low-single-digit). Global rigid PU foam ~$22.2B, ~5.6% CAGR. Growing slowly in real terms, not shrinking. International — FY25 geographic mix: North America 57%, Europe 23%, Latin America 15%, Asia 4%. Surfactants skew NA/LatAm; Polymers ~38% Europe (hence EU-construction exposure). FX-exposed.

Business Quality & Competitive Moat

Is the industry getting more or less competitive?

Near-term less competitive on the supply side (a capital-cycle positive): the broad chemical sector is rationalizing — global plant-closure announcements roughly doubled in 2025; BASF, Dow cutting capacity; European utilization ~74.6%. Stepan itself is closing Fieldsboro NJ and decommissioning Millsdale IL / Stalybridge UK surfactant assets. This supply withdrawal is the precondition for returns to mean-revert up. But this is cyclical discipline, not a structural barrier — when demand recovers, capacity and competition can return. Phthalic anhydride remains chronically oversupplied (China ~57% utilization) with no near-term discipline.

How profitable is the business (ROIC, ROE)?

Poor at the trough. FY25 ROE ~3.9%, after-tax ROIC ~3.6% — both well below ~8–9% WACC; the business is destroying economic value at the consolidated level today. At the 2021–22 peak, ROIC reached ~8–9% and ROE ~12% — i.e., even at the super-cycle peak the business merely reached its cost of capital. Normalized (mid-cycle) ROIC ~6–7% / ROE ~9% only approaches WACC. This is a cost-of-capital business, not a compounder — the decisive evidence against a durable moat.

How profitable is the industry — how many competitors, what barriers to entry?

Surfactants is large but fragmented — only BASF (~16%) and Dow (~14%) hold double-digit share; Stepan is sub-5% (the largest independent merchant producer, not the market leader). Competitors include BASF, Solvay/Syensqo, Clariant, Evonik, Croda, Indorama, Sasol, Pilot, Kao — most multiples of Stepan’s size. Barriers to entry in the commodity laundry/dish core are low (scale and feedstock access only; products are spec-able; large customers can self-supply). The one regulation-created barrier is 1,4-dioxane compliance (NY 1 ppm since 12/31/2023; CA advancing), which favors scaled producers who invested to strip dioxane from ethoxylation — a genuine, filing-confirmed share-shift tailwind, and the standout barrier-to-entry exception.

Can the business be easily understood?

Yes, structurally — a B2B intermediate-chemicals processor converting purchased feedstocks into surfactants, polyols/PA, and specialty ingredients, earning a spread. The complexity is in the normalization math (separating feedstock pass-through from real volume, and trough from mid-cycle earnings), not the business model. Accounting is clean (Deloitte since 2002, unqualified ICFR), which aids understanding.

Can it be undermined by foreign low-cost labor?

Not principally by labor — chemicals manufacturing is capital- and feedstock-intensive, not labor-intensive. The real “low-cost foreign” threat is feedstock-advantaged and capacity-advantaged foreign producers: Southeast-Asian oleochemical producers sit closest to >75% of global CNO/PKO supply, and Chinese phthalic-anhydride overcapacity (~57% utilization) is a structural import/price threat in that sub-segment. Stepan’s defense is regional cost/logistics (local US ethoxylation, freight/import-substitution) and the 1,4-dioxane regulatory moat — not labor cost.

Do brands matter?

No. Stepan is not a consumer brand owner; it sells unbranded intermediates B2B. Buying decisions turn on product performance, price, technical service, qualification/spec-fit, and capacity availability — not brand. (Brand matters for Stepan’s customers — P&G, Unilever, Henkel — not for Stepan.)

What is the nature of competition?

In the commodity core (laundry, dish, phthalic anhydride), price-led — management’s own FY24 disclosure attributes lower surfactant prices to “increased competitive pressure,” and FY25 NA polymer share gains came from a competitor’s PA exit (unstable share = commodity dynamics). In the niches (crop, oilfield, industrial cleaning, specialty/MCT, low-dioxane), competition is on performance, technical service, and qualification — Stepan competes “on bases other than price alone,” but these are a minority of the book.

Customers’ switching costs?

Largely absent in the commodity core — buyers dual-source spec-able intermediates; no single customer is >10% of sales (true in 2023, 2024, 2025); pricing is pass-through, not lock-in. Real switching costs exist only where products are qualified into a regulated formulation: food/pharma MCT (Specialty Products) and certain specialty surfactants/polyols. That is genuine demand captivity, but confined to well under 10% of the company — the consolidated ~3.6% ROIC proves it is not broad enough to lift the whole. Verdict: a bounded regional supply/cost advantage plus a small pocket of demand captivity — no company-wide moat.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet?

A thin hidden-asset cushion. Property is carried at historical cost on a >50-year-old footprint (Millsdale dates to the 1950s), so land may carry trivial cost basis — evidenced by the $30M Millsdale non-operating land parcel sale (P&S signed, closes 2H’26) on a parcel that was effectively invisible in book value. Replacement cost of the network (Pasadena alone ~$265M spent) likely exceeds book. But the cushion is small and soft: $30M is ~2.5% of market cap, and the Q1’26 $62.4M of impairments (Fieldsboro NJ, Millsdale IL, Stalybridge UK) prove some carrying value is not recoverable in an oversupplied commodity — so tangible book (~$49/sh) is a soft floor, not a hard one. The pension is overfunded (US + UK DB plans both net-asset at FY25), a modest unrecognized positive.

Off-balance-sheet liabilities?

Minimal. Operating-lease liability ~$61.4M (Q1’26, already on B/S under ASC 842). Environmental/CERCLA reserves with ~$45M/yr ongoing compliance cost (~$9.8M environmental CapEx FY25) — a recurring cost, partly reserved. No material off-balance-sheet financing, no pension overhang (overfunded), no going-concern or litigation flags in the 36-month filing corpus. The balance-sheet risk is on-sheet leverage and debt duration, not hidden liabilities.

How conservative is the accounting?

Conservative / clean. Deloitte auditor since 2002, unqualified ICFR, no restatements. Company-reported Adjusted EBITDA is conservative — it strips OUT the FY25 $15.9M asset-sale gain, so adjusted EBITDA ($198.9M) is below reported EBITDA ($208.0M) — a green flag (adjusted < reported = non-aggressive). CFO runs well above net income (FY25 CFO $147.9M vs NI $46.9M), driven by heavy non-cash D&A (~$126M), with no accrual red flags (the FY21 working-capital build reversed by FY23). Trough GAAP EPS understates cash generation; this is a quality-of-earnings positive.

How CapEx-hungry is the business?

Moderately, and currently past its peak. Maintenance/baseline CapEx historically ~$80–105M/yr. The 2021–23 surge (~$756M cumulative, ~$350–400M of it growth = Pasadena) spiked CapEx to $301.6M (2022), then normalized to ~$122M (2024–25). FY26 guide $105–115M, of which ~75–80% is maintenance/reliability. Asset-heavy but not capital-destroying once the growth bet completes; the worry is that even at ~$105–115M, FY25 organic FCF (~$25M) is thin relative to the dividend (~$35M).

Capital Allocation & Management

How much FCF does the business generate, how does management use it, what is the philosophy?

Thin at the trough. FCF (CFO − CapEx): 2022 −$140.8M (Pasadena peak), 2023 −$85.5M, 2024 +$39.3M, 2025 +$25.4M, Q1’26 −$14.0M. FY25 FCF (~$25M) did not cover the ~$35M dividend — the gap was plugged with asset-sale proceeds. Uses: dividend (priority, defended), debt paydown (stated priority — LTD-noncurrent down from $438M mid-23 to $341M YE25), and paused buybacks. The philosophy is deleverage + defend the dividend, with growth CapEx now in harvest (Pasadena ramp) rather than build mode. The dividend-vs-deleveraging tension is the central capital-allocation conflict.

Significant acquisitions recently?

None. The activity is the reverse — portfolio pruning: sold SPQI Philippines (Bauan) and Lake Providence LA in Q4’25 (combined ~$15.9M pre-tax gains, with a tolling agreement on SPQI), plus the $30M Millsdale land sale (closes 2H’26). The one large capital decision was organic, not M&A: the ~$265M Pasadena alkoxylation hub (~20% over budget, ~18 months late, started Apr 2025) — value-destructive to date, verdict deferred to the 2026–27 ramp.

Buying back shares?

No — effectively paused 2023–2025. $125.1M remained authorized at 3/31/26, none repurchased in Q1’26. Historical buybacks were modest ($17–25M/yr in 2021–22). The correct call — prioritizing debt paydown and the dividend over repurchases while leverage is elevated.

Issuing large amounts of new shares to insiders?

No — not a dilution story. Stock-based compensation is small (~$5.3–6.0M/yr 2023–25, down from $13.9M in 2022) and share count is stable (~22.69–22.71M). Insider Form 4 activity over ~2024–2026 is routine grants/exercises/tax-withholding; the only open-market purchase in three years was Director Susan Lewis buying 500 shares (~$32K) at $63.53 on 2025-02-27.

Compensation policy of directors/management?

(2026 proxy:) Annual incentive on Corporate Net Income 50% / EBITDA 30% / Free Cash Flow 15% / Safety 5% (FCF + Safety added 2025). LTI performance shares scaled on Corporate Net Income with a ±30% ROIC modifier (year-3 Corporate ROIC, NOPAT/invested-capital). CEO ownership requirement 5x salary; other officers 2.5x. FY25 payout was low by design — NI ($46.9M) fell below the $50M threshold → 0% on the 50%-weighted NI objective; CEO Rojo total comp $4.33M. Above-average alignment for the sector — it does not reward volume/sales growth (avoiding the commodity-chemical share-chase failure mode) and the ROIC modifier directly ties pay to whether Pasadena earns a return. Weakness: heavily absolute (NI-anchored), no relative-TSR metric, so it over-rewards cyclical updrafts and over-punishes troughs regardless of relative execution.

Motivations of management?

A finance-led, founder-family-anchored team. CEO Luis Rojo (ex-CFO, since Oct’24) and CFO Ruben Velasquez (ex-3M, Jul’25) are running a deleverage/cost-out/ROIC agenda consistent with the comp scorecard. Chairman F. Quinn Stepan Jr. holds ~4.6% (insiders ~6.6%) — real skin in the game, though not a controlling block, and the family stake plus the 58-year dividend streak motivate dividend protection strongly (a possible source of conservatism or, in a prolonged trough, of value-suboptimal streak-defense). Three CFOs in ~one year plus a new Key Executive Severance Plan (Nov’25) is some turnover to watch, though the metrics-driven plan mitigates concern.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer?

No to all three. Stepan is a Delaware C-corporation, NYSE-listed common stock ($1 par), CIK 0000094049. US filer (10-K/10-Q). Shareholders receive a 1099-DIV (ordinary qualified dividends), not a K-1; there is no MLP/partnership or ADR structure. No special tax complexity.

Dividend policy?

$0.395/quarter = $1.58/yr, ~3% yield, ~$35M/yr cash cost. 58 consecutive years of annual increases (a Dividend Aristocrat/King-class streak); latest raise ~2.6%. The streak is now a constraint, not a free good — FY25 organic FCF (~$25M) was below the dividend, funded with asset-sale proceeds; GAAP payout ~75% on trough NI but ~31% on normalized NI. Sustainable if Catalyst savings and the Pasadena ramp restore FCF; a cut would confirm the bear case and likely trigger a de-rating. Watch-item, not yet a break.

How profitable is the business?

Low at the trough — FY25 net margin ~2.0% ($46.9M on $2,332.1M), gross margin ~11.6%, operating margin ~3.4%, after-tax ROIC ~3.6%, ROE ~3.9%. Segment split is the key fact: Surfactants (71% of sales) earns only ~4% operating margin; Specialty Products (3.5% of sales) earns ~31% — the only attractive franchise. Normalized profitability is roughly double (mid-cycle ~$280–310M adjusted EBITDA, ~$4.50–5.50 EPS), but even normalized ROIC (~6–7%) only approaches WACC.

Is net income diverging from cash from operations?

Yes — favorably. CFO has run well above net income for three years (2023 $174.9M vs NI $40.2M; 2024 $162.1M vs $50.4M; 2025 $147.9M vs $46.9M), driven by heavy non-cash D&A (~$126M FY25) from the recently-completed CapEx cycle. This is a positive divergence — depreciation-heavy trough GAAP earnings understate cash generation, not the reverse. No working-capital or accrual red flag (the only anomaly, FY21 CFO < NI on an inflation-driven inventory build, reversed by FY23). The Q1’26 GAAP loss is a non-cash restructuring artifact (impairments; <$3M cash impact), with CFO still positive ($16.9M).

Risks & Downside

What factors would cause the stock to decline?

The operative downside drivers:

1. Project Catalyst savings competed away in the no-moat commodity core (the master swing variable) — normalized EBITDA collapses back toward the ~$200M trough.
2. Structural (not cyclical) surfactant volume erosion — private-label trade-down, customer self-supply, foreign capacity.
3. Pasadena ramp stalls (<70% utilization, specialty volumes disappoint) — the ~$265M asset stays a drag.
4. Feedstock (CNO/PKO) spike — pass-through lag re-compresses margins in cost-up quarters.
5. Prolonged European construction trough — pressures the higher-margin Polymers segment.
6. Dividend cut — would confirm the bear case and trigger multiple de-rating.
7. Phthalic-anhydride oversupply (China ~57% util) deepening.
8. Geopolitical/energy shock or tariffs (Iran-region) — feedstock/energy cost inflation (magnitude unquantified).

In the bear scenario (~$25–38/sh), the stock pierces tangible book (~$49/sh) because the impairments prove some book is unrecoverable.

Risk of a catastrophic loss?

Low. The realistic severe-downside case is a continued sub-WACC grind with a dividend cut and a de-rate to ~$25–38 (a ~25–50% drawdown), not a wipeout. Mitigants: clean accounting, overfunded pension, no off-balance-sheet liabilities, laddered notes (2026–33) with $127M revolver availability, hard physical assets, ~6.6% insider ownership, and a diversified (no >10%) customer base. A catastrophic loss would require something exogenous and severe — a major environmental/litigation event (CERCLA exposure exists but is reserved), a covenant breach in a far deeper/longer downcycle, or a feedstock-supply collapse — none of which is evidenced in the filings.

Chance of a total loss?

Remote. Net debt ~$511M (~2.6x EBITDA) against ~$1.2B of equity, hard assets, positive (if thin) FCF and strong CFO, an investment-grade-style covenant-light profile, and a 90±year operating history. The leverage risk is duration (a multi-year trough slowing deleveraging), not solvency. Total-loss probability is negligible barring an extreme, unforeseen event.

Recent News & Events

Has the business environment changed recently?

Yes, on two fronts. (1) Supply-side rationalization accelerated through 2025 (sector plant closures roughly doubled; BASF/Dow cutting), a capital-cycle positive that precedes a returns recovery. (2) Q1’26 marked a discrete inflection — the $65.4M Project Catalyst restructuring charge drove a GAAP loss, formally launching the footprint consolidation. Feedstock (CNO/PKO) volatility and a 2026 geopolitical/energy (Iran-region) overlay are fresh cost-risk variables. This is a low-coverage small cap, so the recent-events read is built from filings and earnings-call transcripts.

Significant acquisitions?

None. Only divestitures/pruning — SPQI Philippines, Lake Providence LA (Q4’25), and the $30M Millsdale land sale (closing 2H’26).

Change in accounting policies?

None material. Auditor Deloitte (since 2002), unqualified ICFR, no restatements. The Q1’26 GAAP loss is a restructuring/impairment charge, not an accounting-policy change. Comp metrics were adjusted in 2025 (added FCF and Safety to the annual incentive) — a pay-design change, not an accounting one.

Recent changes — new markets, facilities, management?

• Facilities: Pasadena TX alkoxylation hub started Apr 2025 (ramping to ~80% util 2026, full 2027); Fieldsboro NJ closing and Millsdale IL / Stalybridge UK assets decommissioning under Project Catalyst by mid-2026; SPQI Philippines and Lake Providence LA divested.
• Management: CEO Luis Rojo (ex-CFO) since Oct’24, replacing Scott Behrens; CFO Ruben Velasquez (ex-3M) since Jul’25; Chairman F. Quinn Stepan Jr. New directors Corning Painter (Orion S.A. CEO, 2025) and Lorinda Burgess (ex-Medtronic Americas CFO). A finance-led team now runs the company.
• Markets: strategic mix-shift toward specialty alkoxylates, low-1,4-dioxane chemistry (regulatory tailwind), MCT (food/pharma), and Tier-2/3 accounts — a repositioning away from the commodity core, not a new end-market per se.

The cluster of changes is net-negative near-term (downcycle, Pasadena drag, restructuring charge, uncovered dividend) but sets up a potential 2026–27 inflection — contingent on the Pasadena ramp, full Catalyst savings, and a cyclical surfactant recovery all converting from plan to fact.

APPENDIX B — Source Appendix

Issuer: Stepan Company · NYSE: SCL · SEC CIK 0000094049 · HQ Northbrook, IL · FY ends December 31. EDGAR filer landing page: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000094049

This appendix catalogs the public primary and secondary sources relied upon, separated Primary / Secondary. The hierarchy applied throughout: primary sources (SEC filings, EDGAR XBRL) are authoritative and every material number is reconciled to a filing; transcripts are management commentary, treated as hypothesis and validated against filings before use; third-party market and valuation data are used only for market data, multiples, and peer comps, each reconciled to filings; industry/regulatory sources provide structural framing only.

1. Primary — SEC Filings (EDGAR, CIK 0000094049)

1.1 Annual Reports (10-K)

Used for: multi-year income statement / balance sheet / cash flow; segment net sales & operating income (Surfactants / Polymers / Specialty Products); MD&A volume-price-FX bridges; non-GAAP EBITDA & net-debt reconciliations; Item 1 Business & Competitive Conditions; 1,4-dioxane / environmental compliance disclosure; Project Catalyst & site-closure notes; Notes 4/6/16/19/20/22.

1.2 Quarterly Reports (10-Q)

Used for: Q1 2026 restructuring (Note 16 — $65.4M charge: $62.4M impairments by site [Fieldsboro NJ $43.0M, Elwood/Millsdale IL $14.3M, Stalybridge UK $5.1M] + decommissioning + termination); Q1’26 net loss $(41.4M) / $(1.81); adjusted NI/EBITDA; debt/cash/net-debt at 3/31/26; $30M Millsdale land P&S (closes 2H’26); quarterly volume-price bridges.

1.3 Material Current Reports (8-K)

The remaining 8-Ks in the corpus are routine quarterly earnings releases and dividend declarations plus 8-K/A amendments.

1.4 Proxy Statements (DEF 14A)

Used for: incentive-comp metrics (Annual Incentive: NI 50% / EBITDA 30% / FCF 15% / Safety 5%; LTI Performance Shares on Corporate NI + ROIC modifier; no relative-TSR); 2025 payout calc; ownership (F. Quinn Stepan Jr. 4.6%; all dirs+EOs 6.6%); ownership requirements; director/officer bios.

1.5 Insider Transactions (Form 3/4/5)

EDGAR ownership corpus, CIK 0000094049, ~Jan 2024 – May 2026: 155 Form 4 + 17 Form 4/A + 9 Form 3 + 1 Form 5 + 1 Form 5/A.

• Only one discretionary open-market PURCHASE (code P): Director Susan Lewis, 500 sh @ $63.53, 2025-02-27 (~$32K). All other activity routine: director annual retainer grants (code A), officer PSU/RSU grants (A), option exercises (M), tax-withholding (F); F. Quinn Stepan Jr. gifts (G) and warrant/trust distribution (W, −138,745 sh Aug-2025, estate/diversification). Insider signal: neutral-to-slightly-soft — no conviction buying at below-book trough, but no discretionary selling.
• EDGAR ownership filings index: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000094049&type=4

2. Primary — EDGAR XBRL Financial Data

Authoritative for US-filer financials; reconciled to the 10-K/10-Q.

3. Primary — Earnings-Call Transcripts

Cited to public transcript sources. Management commentary = hypothesis (validated against filings before use).

Used for: Project Catalyst ($100M pretax savings, ~60% in 2026); Pasadena ramp guidance (~80% util 2026, full 2027); Millsdale land sale; adjusted EBITDA/NI framing; deleveraging priority; dividend-aristocrat (58 consecutive increases) commentary.

4. Secondary — Market & Valuation Data

All third-party aggregated quantitative data is reconciled to filings; EDGAR/10-K remain primary for all financials.

5. Secondary — Industry, Peer & Regulatory Sources

Used for structural/market-size framing only.

Peer financials (public market data): Innospec (IOSP, closest specialty-surfactant peer), Huntsman (HUN), Celanese (CE), Westlake (WLK), Chemours (CC), Koppers (KOP).

End of report.